Gabriel S. Guerreiro
Porto Alegre, RS 90035903, Brazil
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Rifaximin prophylaxis in MASLD‑hepatocellular carcinoma: Lessons from a negative animal model.
Journal: Biomedical reports
Published: April 08, 2024
Firmicutes/Bacteroidetes and Firmicutes/Proteobacteria ratios are associated with worse prognosis in a cohort of Latin American patients with cirrhosis.
Journal: Clinics (Sao Paulo, Brazil)
Published: April 06, 2024
Rifaximin on epigenetics and autophagy in animal model of hepatocellular carcinoma secondary to metabolic-dysfunction associated steatotic liver disease.
Journal: World journal of hepatology
Published: November 03, 2023
Potential Beneficial Effect of Rifaximin in the Prevention of Hepatocellular Carcinoma through the Modulation of the Microbiota in an Experimental Model of Non-alcoholic Fatty Liver Disease.
Journal: Acta gastroenterologica Latinoamericana
Published: June 10, 2023
Changes in the gut microbiota of rats after exposure to the fungicide Mancozeb.
Journal: Toxicology and applied pharmacology
Published: January 14, 2023
Genetic Ancestry, Race, and Severity of Acutely Decompensated Cirrhosis in Latin America.
Journal: Gastroenterology
Published: December 05, 2022
Nicotinamide riboside and dietary restriction effects on gut microbiota and liver inflammatory and morphologic markers in cafeteria diet-induced obesity in rats.
Journal: Nutrition (Burbank, Los Angeles County, Calif.)
Published: November 08, 2022
Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD?
Journal: Hepatology international
Published: November 13, 2020
Showing 1-8 of 8
Last Updated: 09/26/2026